Loading...
Please wait, while we are loading the content...
Similar Documents
Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
| Content Provider | Scilit |
|---|---|
| Author | Landsburg, Daniel J. Hughes, Mitchell E. Koike, Alexa Bond, David Maddocks, Kami J. Guo, Ling Winter, Allison M. Hill, Brian T. Ondrejka, Sarah L. Hsi, Eric D. Nasta, Sunita D. Svoboda, Jakub Schuster, Stephen J. Bogusz, Agata M. |
| Copyright Year | 2019 |
| Description | Key Points The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib. |
| Related Links | https://ashpublications.org/bloodadvances/article-pdf/3/2/132/782706/advances026401.pdf |
| Ending Page | 135 |
| Page Count | 4 |
| Starting Page | 132 |
| DOI | 10.1182/bloodadvances.2018026401 |
| Journal | Blood advances |
| Issue Number | 2 |
| Volume Number | 3 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2019-01-22 |
| Access Restriction | Open |
| Subject Keyword | Hematology Protein Lymphoma Monotherapy Bcl2 Myc Relapsed/refractory Germinal Double Expressor Journal: Blood advances (Vol- 41, Issue- 2) |
| Content Type | Text |
| Resource Type | Article |